Skip to main content

Ipilimumab and Nivolumab

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

  • RegistryNCT07075120
  • PhasePhase 1
  • StatusRecruiting
  • ConditionHepatocellular Carcinoma (HCC)
  • SponsorUniversity of Hawaii
How Ipilimumab and Nivolumab worksNCT070751201 min

What the film says

Read the transcript

This trial is for locally advanced hepatocellular carcinoma, a liver cancer, in adults.

The idea: combine two immunotherapy drugs, ipilimumab and nivolumab, with targeted radiation before surgery. Patients first receive the drugs for nine weeks. Scans then show whether the tumor can be removed. If not, immunotherapy continues with radiation in three to five treatments, and surgery follows once removal is possible.

This pilot phase 1 study plans 15 patients and measures feasibility. At the University of Hawaii in Honolulu, Jared Acoba leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07075120

    Locally advanced hepatocellular carcinoma, adults; Ipilimumab and nivolumab with targeted radiation before surgery; Drugs for nine weeks; scans show whether tumor can be removed; otherwise radiation is added; Pilot phase 1; 15 patients; feasibility (+2 more lines)

The drug

What is being tested.

Immunotherapy combination (Ipilimumab and Nivolumab) targeting CTLA-4 and PD-1 pathways to enhance immune response.

High-dose radiation therapy delivered in 3-5 fractions for local control of tumors in combination with immunotherapy. Radiation dosages are based on the RTOG 1112 trial guidelines to minimize normal tissue exposure.

Additionally, stereotactic body radiotherapy (SBRT) has been shown to enhance survival and local control when combined with systemic therapies like ICIs. However, without surgery, outcomes remain suboptimal, with response rates for ICIs alone at 20-30%, and combination ICI-SBRT treatment showing slightly better results but still a high risk of progression.

The study

How the trial runs.

Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths globally, with Native Hawaiian and Pacific Islander (NHPI) populations experiencing significantly higher mortality rates compared to other groups in Hawaii. This disparity is influenced by factors such as higher prevalence of chronic hepatitis B, non-alcoholic fatty liver disease, limited access to early detection, and delayed diagnoses.

NHPI patients are also underrepresented in clinical trials, limiting the relevance of treatment advances for this population. The standard treatment for HCC is surgical resection; however, many NHPI patients present with unresectable disease. Recent advances with immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, have shown promise in treating advanced HCC and improving survival in previously untreatable cases.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Histologically or cytologically confirmed hepatocellular cancer
  • Solitary tumor >5 cm, OR
  • Unilobar multifocal disease either with >3 tumors or one tumor >3 cm, OR
  • Bilobar disease with adequate future liver remnant, still technically resectable, OR

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.